Basic Information
| Drug ID | DDPD00709 |
|
| Drug Name | Lamivudine | |
| Molecular Weight | 229.256 | |
| Molecular Formula | C8H11N3O3S | |
| CAS Number | 134678-17-4 | |
| SMILES | NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1 | |
| External Links | ||
| DRUGBANK | DB00709 | |
| PubChem Compound | 60825 | |
| PDR | 187 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Log P | -1.4 | - | -1.4 | - | DRUGBANK |
| Melting Point | 161.0 | ℃ | 160-162 | ℃ | DRUGBANK |
| Water Solubility | 70000.0 | mg/L | 70 | mg/ml | DRUGBANK |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Factor | Reference |
|---|---|---|---|---|---|---|---|
| Bioavailability | 86.0 | % | 86±16 | % | Tablet, PO, oral; AIDS,HIV; | DRUGBANK | Bioavailability | 87.0 | % | 87±13 | % | Capsule, PO, Oral; AIDS,HIV; | DRUGBANK | Bioavailability | 86.0 | % | 86±17 | % | PO, oral; Male, men; normal,healthy; | The Pharmacological Basis of Therapeutics |
| C Max | 1500.0 | ng/ml | 1.5±0.5 | mcg/ml | PO, oral; AIDS,HIV; | DRUGBANK | C Max | 1000.0 | ng/ml | 1.0(0.86-1.2) | mcg/ml | Male, men; normal,healthy; | The Pharmacological Basis of Therapeutics |
| T Max | 1.0 | h | 0.5-1.5 | h | Male, men; normal,healthy; | The Pharmacological Basis of Therapeutics | |
| Clearance | 12.0 | L/h | 199.7±56.9 | ml/min | Renal clearance; PO, oral; normal,healthy; | DRUGBANK | Clearance | 16.8 | L/h | 280.4±75.2 | ml/min | Renal clearance; intravenous injection, IV; AIDS,HIV; patients; | DRUGBANK | Clearance | 23.9 | L/h | 398.5±69.1 | ml/min | Total clearance; AIDS,HIV; patients; | DRUGBANK | Clearance | 0.30 | L/h/kg | 4.95±0.75 | ml/min/kg | Children ↑ ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia ↓ ; | The Pharmacological Basis of Therapeutics | Clearance | 0.29 | L/h/kg | 4.8 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 1.3 | L/kg | 1.3±0.4 | L/kg | Apparent volume of distribution; intravenous injection, IV; | gaining weight → ;increasing doses → ; | DRUGBANK | Volume of Distribution | 1.3 | L/kg | 1.30±0.36 | L/kg | The Pharmacological Basis of Therapeutics | Volume of Distribution | 1.3 | L/kg | 1.3 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 6.0 | h | 5-7 | h | normal,healthy; patients; | DRUGBANK | Half-life | 6.0 | h | 5-7 | h | HBV-infected; patients; | DRUGBANK | Half-life | 9.1 | h | 9.11±5.09 | h | Children ↓ ;moderate renal function ↑ ;severe renal function ↑ ; | The Pharmacological Basis of Therapeutics | Half-life | 9.1 | h | 9.1 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Eliminate Route | 67.0 | % | 49-85 | % | Urinary excretion; Male, men; normal,healthy; human, homo sapiens; Unchanged drug; | The Pharmacological Basis of Therapeutics | |
| Protein Binding | 36.0 | % | <36 | % | plasma proteins; | DRUGBANK | Protein Binding | 36.0 | % | <36 | % | Male, men; normal,healthy; human, homo sapiens; | The Pharmacological Basis of Therapeutics |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for neonates | 4.0 | mg/kg/day | 4 | mg/kg/day | PO, oral | Epivir-HBV | lamivudine | PDR |
| Max dose for infants | 10.0 | mg/kg/day | 10 | mg/kg/day | PO, oral | Epivir-HBV | lamivudine | PDR |
| Max dose for infants | 8.0 | mg/kg/day | 8 | mg/kg/day | PO, oral | Epivir-HBV | lamivudine | PDR |
| Max dose for infants | 8.0 | mg/kg/day | 8 | mg/kg/day | PO, oral | Epivir-HBV | lamivudine | PDR |
| Max dose for children | 10.0 | mg/kg/day | 10 | mg/kg/day | PO, oral | Epivir-HBV | lamivudine | PDR |
| Max dose for children | 300.0 | mg/day | 300 | mg/day | PO, oral | Epivir-HBV | lamivudine | PDR |
| Max dose for children | 8.0 | mg/kg/day | 8 | mg/kg/day | PO, oral | Epivir-HBV | lamivudine | PDR |
| Max dose for children | 300.0 | mg/day | 300 | mg/day | PO, oral | Epivir-HBV | lamivudine | PDR |
| Max dose for children | 3.0 | mg/kg/day | 3 | mg/kg/day | PO, oral | Epivir-HBV | lamivudine | PDR |
| Max dose for children | 100.0 | mg/day | 100 | mg/day | PO, oral | Epivir-HBV | lamivudine | PDR |
| Max dose for children | 10.0 | mg/kg/day | 10 | mg/kg/day | PO, oral | Epivir-HBV | lamivudine | PDR |
| Max dose for children | 8.0 | mg/kg/day | 8 | mg/kg/day | PO, oral | Epivir-HBV | lamivudine | PDR |
| Max dose for adolescents | 300.0 | mg/day | 300 | mg/day | PO, oral | Epivir-HBV | lamivudine | PDR |
| Max dose for adolescents | 3.0 | mg/kg/day | 3 | mg/kg/day | PO, oral | Epivir-HBV | lamivudine | PDR |
| Max dose for adolescents | 100.0 | mg/day | 100 | mg/day | PO, oral | Epivir-HBV | lamivudine | PDR |
| Max dose for adults | 300.0 | mg/day | 300 | mg/day | PO, oral | Epivir-HBV | lamivudine | PDR |
| Max dose for adults | 100.0 | mg/day | 100 | mg/day | PO, oral | Epivir-HBV | lamivudine | PDR |
| Max dose for geriatric | 300.0 | mg/day | 300 | mg/day | PO, oral | Epivir-HBV | lamivudine | PDR |
| Max dose for geriatric | 100.0 | mg/day | 100 | mg/day | PO, oral | Epivir-HBV | lamivudine | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1